From 2018 to 2025, 340B purchases at list prices more than tripled in size and grew three times faster than the rest of the U.S. drug market. This analysis examines how purchases reached between $180 billion and $200 billion in 2025, how growth is concentrating across channels and disease areas, and which regulatory and market forces may accelerate or moderate future expansion.

Download this white paper to:

• Understand how 340B purchases more than tripled from 2018 to 2025 and approached the scale of Medicare Part D.
• See which channels and disease areas are driving the largest share of program growth.
• Learn how contract pharmacy mandates, patient eligibility ambiguity, Maximum Fair Price implementation, and potential rebate models may affect future trajectory.
• Access a data-driven view of the program’s size, composition, and emerging policy implications